Evidence map›Paper›PMID 27716795›Full record

ArticlePLoS computational biology2016

Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.

Jianhui Tian, Cesar A López, Cynthia A Derdeyn, Morris S Jones, Abraham Pinter, Bette Korber, S Gnanakaran

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Visualization of the HIV-1 Env glycan shield across scales.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  6. Review
  7. Article
  8. All-atom virus simulations.Current opinion in virology · 2018
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Jianhui TianTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Cesar A LópezTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Cynthia A DerdeynDepartment of Pathology and Laboratory Medicine and Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.
Morris S JonesUniversity of California Berkeley, School of Public Health, Berkeley, California, United States of America.
Abraham PinterNew Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Bette KorberTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
S GnanakaranTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Los Alamos National Laboratory · USEmory University · USOak Ridge National Laboratory · USRutgers, The State University of New Jersey · USUniversity of California, Berkeley · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HARRISON, STEPHEN COPLAN · 2012 to 2018
$204.7M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Viral Immunology CoreP01AI088610 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PINTER, ABRAHAM · 2010 to 2014
$15.3M
Role of V1V2 in HIV transmission and pathogenesisR01AI058706 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DERDEYN, CYNTHIA ANN · 2004 to 2016
$6.7M
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120R01AI102718 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PINTER, ABRAHAM · 2012 to 2015
$2.7M
NIAID NIH HHS P01 AI088610NIAID NIH HHS R01 AI058706NIAID NIH HHS R01 AI102718NIAID NIH HHS UM1 AI100645NIH HHS P51 OD011132
6 · The paper itself

Abstract

Heavy glycosylation of the envelope (Env) surface subunit, gp120, is a key adaptation of HIV-1; however, the precise effects of glycosylation on the folding, conformation and dynamics of this protein are poorly understood. Here we explore the patterns of HIV-1 Env gp120 glycosylation, and particularly the enrichment in glycosylation sites proximal to the disulfide linkages at the base of the surface-exposed variable domains. To dissect the influence of glycans on the conformation these regions, we focused on an antigenic peptide fragment from a disulfide bridge-bounded region spanning the V1 and V2 hyper-variable domains of HIV-1 gp120. We used replica exchange molecular dynamics (MD) simulations to investigate how glycosylation influences its conformation and stability. Simulations were performed with and without N-linked glycosylation at two sites that are highly conserved across HIV-1 isolates (N156 and N160); both are contacts for recognition by V1V2-targeted broadly neutralizing antibodies against HIV-1. Glycosylation stabilized the pre-existing conformations of this peptide construct, reduced its propensity to adopt other secondary structures, and provided resistance against thermal unfolding. Simulations performed in the context of the Env trimer also indicated that glycosylation reduces flexibility of the V1V2 region, and provided insight into glycan-glycan interactions in this region. These stabilizing effects were influenced by a combination of factors, including the presence of a disulfide bond between the Cysteines at 131 and 157, which increased the formation of beta-strands. Together, these results provide a mechanism for conservation of disulfide linkage proximal glycosylation adjacent to the variable domains of gp120 and begin to explain how this could be exploited to enhance the immunogenicity of those regions. These studies suggest that glycopeptide immunogens can be designed to stabilize the most relevant Env conformations to focus the immune response on key neutralizing epitopes.

Indexed as

GlycosylationBinding SitesHIV Envelope Protein gp120Immunodominant EpitopesMolecular Docking SimulationProtein BindingProtein DomainsSingle-Chain Antibodiesgp120 protein, Human immunodeficiency virus 1HIV Envelope Protein gp120Immunodominant EpitopesSingle-Chain Antibodies

Identifiers

PMID27716795
PMCPMC5055340
OpenAlexW2528042153

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.